Literature DB >> 33108180

Rapid Analysis of Reduced Antibody Drug Conjugate by Online LC-MS/MS with Fourier Transform Ion Cyclotron Resonance Mass Spectrometry.

Eli J Larson1, Yanlong Zhu2,3, Zhijie Wu1, Bifan Chen1, Zhaorui Zhang4, Shiyue Zhou4, Linjie Han4, Qunying Zhang4, Ying Ge1,2,3.   

Abstract

Antibody drug conjugates (ADCs), which harness the high targeting specificity of monoclonal antibodies (mAb) with the potency of small molecule therapeutics, are one of the fastest growing pharmaceutical classes. Nevertheless, ADC conjugation techniques and processes may introduce intrinsic heterogeneity including primary sequence variants, varied drug-to-antibody ratio (DAR) species, and drug positional isomers, which must be monitored to ensure the safety and efficacy of ADCs. Liquid chromatography coupled to mass spectrometry (LC-MS) is a powerful tool for characterization of ADCs. However, the conventional bottom-up MS analysis workflows require an enzymatic digestion step which can be time consuming and may introduce artifactual modifications. Herein, we develop an online LC-MS/MS method for rapid analysis of reduced ADCs without digestion, enabling determination of DAR, characterization of the primary sequence, and localization of the drug conjugation site of the ADC using high-resolution Fourier transform ion cyclotron resonance (FTICR) MS. Specifically, a model cysteine-linked ADC was reduced to generate six unique subunits: light chain (Lc) without drug (Lc0), Lc with 1 drug (Lc1), heavy chain (Hc) without drug (Hc0), and Hc with 1-3 drugs (Hc1-3, respectively). A concurrent reduction strategy is applied to assess ADC subunits in both the partially reduced (intrachain disulfide bonds remain intact) and fully reduced (all disulfide bonds are cleaved) forms. The entire procedure including the sample preparation and LC-MS/MS takes less than 55 min, enabling rapid multiattribute analysis of ADCs.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33108180      PMCID: PMC9463631          DOI: 10.1021/acs.analchem.0c03152

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   8.008


  34 in total

1.  Deamidation of -Asn-Gly- sequences during sample preparation for proteomics: Consequences for MALDI and HPLC-MALDI analysis.

Authors:  Oleg V Krokhin; Mihaela Antonovici; Werner Ens; John A Wilkins; Kenneth G Standing
Journal:  Anal Chem       Date:  2006-09-15       Impact factor: 6.986

2.  Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function.

Authors:  Bernhard Antes; Sabine Amon; Andreas Rizzi; Susi Wiederkum; Manuela Kainer; Oliver Szolar; Markus Fido; Ralf Kircheis; Andreas Nechansky
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-01-26       Impact factor: 3.205

3.  Characterization of antibody drug conjugate positional isomers at cysteine residues by peptide mapping LC-MS analysis.

Authors:  Marie-Claire Janin-Bussat; Marina Dillenbourg; Nathalie Corvaia; Alain Beck; Christine Klinguer-Hamour
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-12-24       Impact factor: 3.205

Review 4.  Current possibilities of liquid chromatography for the characterization of antibody-drug conjugates.

Authors:  Balázs Bobály; Sandrine Fleury-Souverain; Alain Beck; Jean-Luc Veuthey; Davy Guillarme; Szabolcs Fekete
Journal:  J Pharm Biomed Anal       Date:  2017-06-24       Impact factor: 3.935

5.  High-Resolution Accurate-Mass Mass Spectrometry Enabling In-Depth Characterization of in Vivo Biotransformations for Intact Antibody-Drug Conjugates.

Authors:  Jintang He; Dian Su; Carl Ng; Luna Liu; Shang-Fan Yu; Thomas H Pillow; Geoffrey Del Rosario; Martine Darwish; Byoung-Chul Lee; Rachana Ohri; Hongxiang Zhou; Xueji Wang; Jiawei Lu; Surinder Kaur; Keyang Xu
Journal:  Anal Chem       Date:  2017-05-03       Impact factor: 6.986

6.  Drug Loading and Distribution of ADCs After Reduction or IdeS Digestion and Reduction.

Authors:  Elsa Wagner-Rousset; Olivier Colas; Yannis-Nicolas François; Sabine Heinisch; Davy Guillarme; Sarah Cianférani; Alain Beck
Journal:  Methods Mol Biol       Date:  2020

7.  Analysis of Monoclonal Antibodies in Human Serum as a Model for Clinical Monoclonal Gammopathy by Use of 21 Tesla FT-ICR Top-Down and Middle-Down MS/MS.

Authors:  Lidong He; Lissa C Anderson; David R Barnidge; David L Murray; Christopher L Hendrickson; Alan G Marshall
Journal:  J Am Soc Mass Spectrom       Date:  2017-02-28       Impact factor: 3.109

8.  MASH Explorer: A Universal Software Environment for Top-Down Proteomics.

Authors:  Zhijie Wu; David S Roberts; Jake A Melby; Kent Wenger; Molly Wetzel; Yiwen Gu; Sudharshanan Govindaraj Ramanathan; Elizabeth F Bayne; Xiaowen Liu; Ruixiang Sun; Irene M Ong; Sean J McIlwain; Ying Ge
Journal:  J Proteome Res       Date:  2020-08-24       Impact factor: 4.466

9.  Antibody variable region glycosylation: position effects on antigen binding and carbohydrate structure.

Authors:  A Wright; M H Tao; E A Kabat; S L Morrison
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

10.  Toward an Optimized Workflow for Middle-Down Proteomics.

Authors:  Alba Cristobal; Fabio Marino; Harm Post; Henk W P van den Toorn; Shabaz Mohammed; Albert J R Heck
Journal:  Anal Chem       Date:  2017-03-10       Impact factor: 6.986

View more
  2 in total

Review 1.  New Technologies Bloom Together for Bettering Cancer Drug Conjugates.

Authors:  Yiming Jin; Shahab Edalatian Zakeri; Raman Bahal; Andrew J Wiemer
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

2.  Top-down proteomics: challenges, innovations, and applications in basic and clinical research.

Authors:  Kyle A Brown; Jake A Melby; David S Roberts; Ying Ge
Journal:  Expert Rev Proteomics       Date:  2020-12-17       Impact factor: 3.940

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.